AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6355542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30778028 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate, up to 100 mg daily for three months
Number of subjects: 66
Study 30778028 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture, 12 sessions (3 sessions a week) for three months
Number of subjects: 66
Study 30778028 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA), 155-195 units for three months
Number of subjects: 66
Study 30169112 — intervention group
Group type: EXPERIMENTAL
Intervention: Short time to surgery (TTS <48 hours)
Number of subjects: 228
Study 30169112 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate time to surgery (TTS 48-72 hours)
Number of subjects: 228
Study 30169112 — intervention group
Group type: COMPARATOR
Intervention: Long time to surgery (TTS >72 hours)
Number of subjects: 228
Study 30169112 — intervention group
Group type: EXPERIMENTAL
Intervention: Short TTS
Number of subjects: 228
Study 30169112 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate TTS
Number of subjects: 228
Study 30169112 — intervention group
Group type: COMPARATOR
Intervention: Long TTS
Number of subjects: 228
Study 30169112 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 228
Study 26888724 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM screening at general practitioners (GP)
Number of subjects: 0
Study 26888724 — intervention group
Group type: COMPARATOR
Intervention: GDM screening at hospital settings
Number of subjects: 0
Study 24731891 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender inhalation based on sesame oil
Number of subjects: 96
Study 24731891 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sesame oil only)
Number of subjects: 96
Study 22134152 — intervention group
Group type: COMPARATOR
Intervention: LPV/r-based regimen (n = 99)
Number of subjects: 195
Study 22134152 — intervention group
Group type: EXPERIMENTAL
Intervention: NVP-based regimen (n = 96)
Number of subjects: 195
Study 18930550 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative 5-fluorouracil (5-FU) 50 mg/ml for 5 minutes
Number of subjects: 103
Study 18930550 — intervention group
Group type: COMPARATOR
Intervention: Intraoperative mitomycin C (MMC) 0.2 mg/ml for 2 minutes
Number of subjects: 103
Study 18930550 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 103
Study 17215195 — intervention group
Group type: EXPERIMENTAL
Intervention: Inulin (0.25 g/kg/d for 3 weeks)
Number of subjects: 14
Study 15827896 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine 20 mg/kg, thrice weekly for 6 months
Number of subjects: 113
Study 15827896 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 12118640 — intervention group
Group type: EXPERIMENTAL
Intervention: Sweeping of membranes
Number of subjects: 120
Study 12118640 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 120
Study 9587725 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 3 mg kg‐1 (n = 20) administered intravenously at the beginning of wound closure
Number of subjects: 40
Study 9587725 — intervention group
Group type: COMPARATOR
Intervention: Saline (n = 20)
Number of subjects: 40
Study 9587725 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 3 mg kg‐1 (n = 20)
Number of subjects: 40
Study 8790652 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg on the first day, followed by 100 mg for the next nine days)
Number of subjects: 140
Study 8790652 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 140
Study 8790652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 2839998 — intervention group
Group type: EXPERIMENTAL
Intervention: m-chlorophenylpiperazine
Number of subjects: 8
Study 2839998 — intervention group
Group type: COMPARATOR
Intervention: Fenfluramine
Number of subjects: 8
Study 2839998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2839998 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine
Number of subjects: 8
Study 4985446 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet injection of diluted smallpox vaccine with a titre of 10(7) TCID(50)/ml
Number of subjects: 156
Study 4985446 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet injection of diluted smallpox vaccine with a titre of 10(6) TCID(50)/ml
Number of subjects: 156
Study 4985446 — intervention group
Group type: COMPARATOR
Intervention: Multiple-pressure inoculation of undiluted vaccine
Number of subjects: 156
Study 31272265 — intervention group
Group type: EXPERIMENTAL
Intervention: Transverse incision
Number of subjects: 86
Study 31272265 — intervention group
Group type: COMPARATOR
Intervention: Longitudinal incision
Number of subjects: 86
Study 28410087 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm (sedation management)
Number of subjects: 3438
Study 28410087 — intervention group
Group type: COMPARATOR
Intervention: Control arm (standard care)
Number of subjects: 3438
Study 28410087 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of Black children
Number of subjects: 3438
Study 28410087 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of Hispanic children
Number of subjects: 3438
Study 28410087 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents of White children
Number of subjects: 3438
Study 25459893 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50mg
Number of subjects: 70
Study 25459893 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 24124428 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent lifestyle modification program
Number of subjects: 0
Study 24124428 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 21356061 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy diet (LED) for 8 weeks followed by 24 weeks of dietary instruction
Number of subjects: 0
Study 21356061 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 21356061 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy diet (LED)
Number of subjects: 0
Study 19660515 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental mouth rinses with varying concentrations of tin (800 to 2800 ppm) and fluoride (250 to 500 ppm)
Number of subjects: 0
Study 19660515 — intervention group
Group type: COMPARATOR
Intervention: Commercially available tin-containing mouth rinse (409 ppm Sn(2+), 250 ppm F(‐))
Number of subjects: 0
Study 19660515 — intervention group
Group type: COMPARATOR
Intervention: Negative control group (no treatment)
Number of subjects: 0
Study 17334580 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue antibody prevalence
Number of subjects: 1260
Study 17334580 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported case incidence during 1996, 1997, and 1998 epidemics
Number of subjects: 1260
Study 17334580 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidemiological surveillance data analysis
Number of subjects: 1260
Study 15334857 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) 5000 U subcutaneously every 12 hours
Number of subjects: 0
Study 15334857 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin (UFH) 5000 U subcutaneously every 8 hours
Number of subjects: 0
Study 15334857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15334857 — intervention group
Group type: COMPARATOR
Intervention: Low-molecular-weight heparins
Number of subjects: 0
Study 11710505 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestibular exercises
Number of subjects: 0
Study 11710505 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (plus an antiviral agent?)
Number of subjects: 0
Study 11710505 — intervention group
Group type: COMPARATOR
Intervention: Drug treatment for viral inflammation
Number of subjects: 0
Study 9024022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate salt 12.5 mg
Number of subjects: 635
Study 9024022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate salt 25 mg
Number of subjects: 635
Study 9024022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron mesylate salt 50 mg
Number of subjects: 635
Study 9024022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 635
Study 9024022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolasetron
Number of subjects: 635
Study 7908187 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous beta‐blocking agents
Number of subjects: 0
Study 7908187 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose‐insulin‐potassium (GIK) therapy
Number of subjects: 0
Study 7908187 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer anticoagulant and antithrombotic agents (hirudin and Hirulog)
Number of subjects: 0
Study 7908187 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer thrombolytic drugs (recombinant plasminogen activator - r‐PA)
Number of subjects: 0
Study 7908187 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant and emulsifying agents (Rheothrx)
Number of subjects: 0
Study 3302654 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (650 mg)
Number of subjects: 21
Study 3302654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 31331286 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 0
Study 31331286 — intervention group
Group type: COMPARATOR
Intervention: Active control (healthy diet)
Number of subjects: 0
Study 29663389 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 24
Study 25753889 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 68
Study 25753889 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 68
Study 24382836 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Ultrasound (US)
Number of subjects: 60
Study 24382836 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo Ultrasound (US)
Number of subjects: 60
Study 24382836 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Low-Level Laser Therapy (LLLT)
Number of subjects: 60
Study 24382836 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo Low-Level Laser Therapy (LLLT)
Number of subjects: 60
Study 24382836 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 60
Study 23043572 — intervention group
Group type: EXPERIMENTAL
Intervention: High pressure port system
Number of subjects: 94
Study 23043572 — intervention group
Group type: COMPARATOR
Intervention: Standard port system
Number of subjects: 94
Study 19221039 — intervention group
Group type: EXPERIMENTAL
Intervention: WT1 mutations
Number of subjects: 617
Study 19221039 — intervention group
Group type: EXPERIMENTAL
Intervention: WT1(mut)/FLT3-ITD(pos) genotype
Number of subjects: 617
Study 17467848 — intervention group
Group type: EXPERIMENTAL
Intervention: gemcitabine 1250mg/m(2) plus cisplatin 70mg/m(2) (GC arm)
Number of subjects: 102
Study 17467848 — intervention group
Group type: COMPARATOR
Intervention: gemcitabine 1000mg/m(2) plus vinorelbine 25mg/m(2) followed by gemcitabine 1000mg/m(2) plus ifosfamide 2000mg/m(2) (GV-GI arm)
Number of subjects: 102
Study 15053911 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer (RMGIC) restorations
Number of subjects: 640
Study 15053911 — intervention group
Group type: COMPARATOR
Intervention: Conventional glass ionomer (GIC) restorations
Number of subjects: 640
Study 11935652 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunocytochemistry for epithelial cytokeratin markers
Number of subjects: 0
Study 11935652 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative monitoring of disseminated tumor cells in the bone marrow
Number of subjects: 0
Study 11935652 — intervention group
Group type: EXPERIMENTAL
Intervention: New molecular biology techniques for MRD phenotyping
Number of subjects: 0
Study 11935652 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for disseminated tumor cells
Number of subjects: 0
Study 8181024 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide-type diuretic or low-dose loop diuretic
Number of subjects: 0
Study 8181024 — intervention group
Group type: EXPERIMENTAL
Intervention: Loop diuretic
Number of subjects: 0
Study 8181024 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-dose loop diuretic combined with thiazide-type diuretic
Number of subjects: 0
Study 8181024 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent intravenous loop diuretic; short-term infusion of a loop diuretic; intensified combination oral diuretic therapy; intravenous positive inotropic therapy; ultrafiltration or dialysis
Number of subjects: 0
Study 8181024 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrolyte replacement guidelines
Number of subjects: 0
Study 8181024 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium retention score
Number of subjects: 0
Study 2691821 — intervention group
Group type: EXPERIMENTAL
Intervention: 312 g of carbohydrate (H)
Number of subjects: 0
Study 2691821 — intervention group
Group type: COMPARATOR
Intervention: 45 g of carbohydrate (L)
Number of subjects: 0
Study 2691821 — intervention group
Group type: COMPARATOR
Intervention: 156 g of carbohydrate (M)
Number of subjects: 0
Study 2691821 — intervention group
Group type: COMPARATOR
Intervention: 0 g of carbohydrate (P)
Number of subjects: 0
Study 4557308 — intervention group
Group type: EXPERIMENTAL
Intervention: BX24 300 mg daily
Number of subjects: 48
Study 4557308 — intervention group
Group type: EXPERIMENTAL
Intervention: BX24 600 mg daily
Number of subjects: 48
Study 4557308 — intervention group
Group type: EXPERIMENTAL
Intervention: BX24 1200 mg daily
Number of subjects: 48
Study 4557308 — intervention group
Group type: COMPARATOR
Intervention: Carbenoxolone sodium 300 mg daily
Number of subjects: 48
Study 4557308 — intervention group
Group type: EXPERIMENTAL
Intervention: BX24 300 mg daily with zinc sulphate 660 mg daily
Number of subjects: 48
Study 4557308 — intervention group
Group type: EXPERIMENTAL
Intervention: BX24 300 mg daily without zinc sulphate
Number of subjects: 48
Study 4557308 — intervention group
Group type: COMPARATOR
Intervention: Carbenoxolone sodium with zinc sulphate
Number of subjects: 48
Study 4557308 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A 50,000 units daily
Number of subjects: 48
Study 4557308 — intervention group
Group type: COMPARATOR
Intervention: Vitamin A withheld
Number of subjects: 48
Study 30772848 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal microbiota transplantation (FMT) plus standard of care
Number of subjects: 32
Study 30772848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 28766349 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF administered at 10:00
Number of subjects: 48
Study 28766349 — intervention group
Group type: EXPERIMENTAL
Intervention: G-CSF administered at 14:00
Number of subjects: 48
Study 25500952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold exposure with fasting for 54 hours
Number of subjects: 0
Study 25500952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-stimulated glucose uptake in BAT
Number of subjects: 0
Study 25500952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold exposure
Number of subjects: 0
Study 24235214 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary vitamin D3 (1, 10, or 20 times the NRC recommended level of 200 IU/kg)
Number of subjects: 1872
Study 24235214 — intervention group
Group type: COMPARATOR
Intervention: High stocking density (16 birds/m²)
Number of subjects: 1872
Study 20732799 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones group (200 mg of Glycine max, 80 mg of isoflavone)
Number of subjects: 87
Study 20732799 — intervention group
Group type: COMPARATOR
Intervention: Control group (1200 kcal diet and exercise)
Number of subjects: 87
Study 19567350 — intervention group
Group type: EXPERIMENTAL
Intervention: AMX-SUL 1g/0.5g infused over 30 min
Number of subjects: 4
Study 19567350 — intervention group
Group type: EXPERIMENTAL
Intervention: AMX-SUL 1g/1g infused over 30 min
Number of subjects: 4
Study 19567350 — intervention group
Group type: EXPERIMENTAL
Intervention: AMX-SUL 2g/0.5g infused over 30 min
Number of subjects: 4
Study 19567350 — intervention group
Group type: EXPERIMENTAL
Intervention: AMX-SUL 1g/1g infused over 3h
Number of subjects: 4
Study 19567350 — intervention group
Group type: EXPERIMENTAL
Intervention: AMX-SUL 1g/0.5g infused over 3h
Number of subjects: 4
Study 16776849 — intervention group
Group type: EXPERIMENTAL
Intervention: oxidized mannan‐MUC1
Number of subjects: 31
Study 16776849 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 31
Study 12972984 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose right unilateral electroconvulsive therapy (approximately 2.25 times seizure threshold)
Number of subjects: 54
Study 12972984 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose right unilateral electroconvulsive therapy (greater than 2.25 times seizure threshold)
Number of subjects: 54
Study 12972984 — intervention group
Group type: COMPARATOR
Intervention: Right unilateral electroconvulsive therapy (both doses)
Number of subjects: 54
Study 10940089 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan (2.5 mg orally)
Number of subjects: 347
Study 10940089 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan (50 mg orally)
Number of subjects: 347
Study 9009937 — intervention group
Group type: EXPERIMENTAL
Intervention: S&G/block (1% lidocaine bilateral GPN blocks)
Number of subjects: 11
Study 9009937 — intervention group
Group type: COMPARATOR
Intervention: S&G (2% viscous lidocaine swish and gargle)
Number of subjects: 11
Study 9009937 — intervention group
Group type: EXPERIMENTAL
Intervention: S&G/spray (2% viscous lidocaine swish and gargle + 10% lidocaine spray)
Number of subjects: 11
Study 7932402 — intervention group
Group type: EXPERIMENTAL
Intervention: ampicillin/sulbactam
Number of subjects: 76
Study 7932402 — intervention group
Group type: COMPARATOR
Intervention: standard therapy (ampicillin, gentamicin and clindamycin)
Number of subjects: 76
Study 3422562 — intervention group
Group type: EXPERIMENTAL
Intervention: Permucosal needle drainage
Number of subjects: 52
Study 3422562 — intervention group
Group type: COMPARATOR
Intervention: Incision and drainage
Number of subjects: 52
Study 30099402 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain education
Number of subjects: 40
Study 30099402 — intervention group
Group type: COMPARATOR
Intervention: Guideline-based physiotherapy treatment (control)
Number of subjects: 40
Study 26632161 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary (IC) administration of eptifibatide
Number of subjects: 76
Study 26632161 — intervention group
Group type: COMPARATOR
Intervention: Intravenous (IV) administration of eptifibatide
Number of subjects: 76
Study 25446521 — intervention group
Group type: EXPERIMENTAL
Intervention: Thenar palmar tape application with pressure
Number of subjects: 45
Study 25446521 — intervention group
Group type: EXPERIMENTAL
Intervention: Thenar palmar tape application without pressure
Number of subjects: 45
Study 25446521 — intervention group
Group type: COMPARATOR
Intervention: Control group (no taping)
Number of subjects: 45
Study 23890168 — intervention group
Group type: EXPERIMENTAL
Intervention: Transrectus sheath preperitoneal procedure (TREPP)
Number of subjects: 0
Study 23890168 — intervention group
Group type: COMPARATOR
Intervention: Transinguinal preperitoneal procedure (control)
Number of subjects: 0
Study 21718184 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphatidylcholine/deoxycholic acid
Number of subjects: 75
Study 21718184 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 75
Study 21718184 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjonctyl®
Number of subjects: 75
Study 17610527 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-SOD 20 mg
Number of subjects: 8
Study 17610527 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-SOD 40 mg
Number of subjects: 8
Study 17610527 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-SOD 80 mg
Number of subjects: 8
Study 17610527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 16927761 — intervention group
Group type: EXPERIMENTAL
Intervention: Air endo‐tamponade (complete fluid‐air exchange)
Number of subjects: 40
Study 16927761 — intervention group
Group type: COMPARATOR
Intervention: BSS Plus (control group)
Number of subjects: 40
Study 16927761 — intervention group
Group type: EXPERIMENTAL
Intervention: Air endo‐tamponade
Number of subjects: 40
Study 12586451 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 40
Study 12586451 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 40
Study 12586451 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall response rate
Number of subjects: 40
Study 11115156 — intervention group
Group type: EXPERIMENTAL
Intervention: Alitretinoin gel (0.05% or 0.1% applied twice daily for the first 2 weeks and up to 4 times daily thereafter)
Number of subjects: 115
Study 11115156 — intervention group
Group type: COMPARATOR
Intervention: Untreated control lesions
Number of subjects: 115
Study 11115156 — intervention group
Group type: EXPERIMENTAL
Intervention: Alitretinoin gel
Number of subjects: 115
Study 9154995 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-II (A-II) at pressor doses (8.44 ng/kg/min)
Number of subjects: 8
Study 9154995 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-II (A-II) at subpressor doses (0.62 ng/kg/min)
Number of subjects: 8
Study 8425695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CyA), 3 mg.kg‐1.day‐1
Number of subjects: 349
Study 8425695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 349
Study 3322166 — intervention group
Group type: EXPERIMENTAL
Intervention: 300‐kcal mixed diet with exercise training
Number of subjects: 40
Study 3322166 — intervention group
Group type: COMPARATOR
Intervention: 300‐kcal mixed diet alone
Number of subjects: 40
Study 31710250 — intervention group
Group type: EXPERIMENTAL
Intervention: CARE-call system
Number of subjects: 100
Study 31710250 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 100
Study 30243294 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane-based inhalational anesthesia (SEV group)
Number of subjects: 80